论文部分内容阅读
1964年首次发表了心得安用于高血压治疗有效的报告,1967年Lands将β受体分为β_1和β_2二大类,此后β阻滞剂的药理学研究和临床应用进展迅速,至今它已成为治疗高血压药物中的主要一大类型。氨酰心安(atenolol)是继心得安之后投入临床使用的又一重要β阻滞剂,具有心脏选择性而没有内源性拟交感作用和膜稳定作用,属β_1受体阻滞剂。据我们多年来的实践
For the first time in 1964, propranolol was reported to be effective in the treatment of hypertension. Lands classified β receptors into β 1 and β 2 in 1967, and the pharmacological study and clinical application of β blockers progressed rapidly so far. Become a major type of drug in the treatment of hypertension. Atenolol is another important β-blocker that has been put into clinical use after propranolol. It has cardiac selectivity without endogenous sympathomimetic and membrane stabilizing effects, and is a beta-1 receptor blocker. According to our many years of practice